nodes	percent_of_prediction	percent_of_DWPC	metapath
Pentazocine—EBP—Sirolimus—Temsirolimus—kidney cancer	0.0123	0.306	CbGdCrCtD
Pentazocine—EBP—Sirolimus—Everolimus—kidney cancer	0.0123	0.306	CbGdCrCtD
Pentazocine—EBP—Temsirolimus—Everolimus—kidney cancer	0.0123	0.306	CbGdCrCtD
Pentazocine—EBP—Azacitidine—Gemcitabine—kidney cancer	0.00332	0.0823	CbGdCrCtD
Pentazocine—Urinary retention—Capecitabine—kidney cancer	0.00284	0.00296	CcSEcCtD
Pentazocine—Somnolence—Everolimus—kidney cancer	0.00283	0.00295	CcSEcCtD
Pentazocine—Dizziness—Temsirolimus—kidney cancer	0.00283	0.00295	CcSEcCtD
Pentazocine—Dry mouth—Sorafenib—kidney cancer	0.00282	0.00294	CcSEcCtD
Pentazocine—Hypertension—Sunitinib—kidney cancer	0.00281	0.00293	CcSEcCtD
Pentazocine—Ulcer—Doxorubicin—kidney cancer	0.0028	0.00292	CcSEcCtD
Pentazocine—Insomnia—Erlotinib—kidney cancer	0.00278	0.0029	CcSEcCtD
Pentazocine—Decreased appetite—Vinblastine—kidney cancer	0.00278	0.0029	CcSEcCtD
Pentazocine—Decreased appetite—Everolimus—kidney cancer	0.00277	0.00289	CcSEcCtD
Pentazocine—Anaphylactic shock—Sorafenib—kidney cancer	0.00277	0.00288	CcSEcCtD
Pentazocine—Diarrhoea—Pazopanib—kidney cancer	0.00276	0.00288	CcSEcCtD
Pentazocine—Dyspnoea—Erlotinib—kidney cancer	0.00274	0.00286	CcSEcCtD
Pentazocine—Constipation—Vinblastine—kidney cancer	0.00273	0.00285	CcSEcCtD
Pentazocine—Constipation—Everolimus—kidney cancer	0.00272	0.00284	CcSEcCtD
Pentazocine—Vomiting—Temsirolimus—kidney cancer	0.00272	0.00284	CcSEcCtD
Pentazocine—Shock—Sorafenib—kidney cancer	0.00272	0.00283	CcSEcCtD
Pentazocine—Dry mouth—Sunitinib—kidney cancer	0.00271	0.00283	CcSEcCtD
Pentazocine—Dermatitis—Temsirolimus—kidney cancer	0.0027	0.00281	CcSEcCtD
Pentazocine—Chills—Gemcitabine—kidney cancer	0.0027	0.00281	CcSEcCtD
Pentazocine—Toxic epidermal necrolysis—Capecitabine—kidney cancer	0.00269	0.0028	CcSEcCtD
Pentazocine—Headache—Temsirolimus—kidney cancer	0.00268	0.0028	CcSEcCtD
Pentazocine—Decreased appetite—Erlotinib—kidney cancer	0.00267	0.00278	CcSEcCtD
Pentazocine—Dizziness—Pazopanib—kidney cancer	0.00267	0.00278	CcSEcCtD
Pentazocine—Anorexia—Sorafenib—kidney cancer	0.00264	0.00275	CcSEcCtD
Pentazocine—Feeling abnormal—Vinblastine—kidney cancer	0.00264	0.00275	CcSEcCtD
Pentazocine—Constipation—Erlotinib—kidney cancer	0.00263	0.00274	CcSEcCtD
Pentazocine—Feeling abnormal—Everolimus—kidney cancer	0.00262	0.00274	CcSEcCtD
Pentazocine—Shock—Sunitinib—kidney cancer	0.00262	0.00273	CcSEcCtD
Pentazocine—Vomiting—Pazopanib—kidney cancer	0.00257	0.00267	CcSEcCtD
Pentazocine—Nausea—Temsirolimus—kidney cancer	0.00254	0.00265	CcSEcCtD
Pentazocine—Dermatitis—Pazopanib—kidney cancer	0.00254	0.00265	CcSEcCtD
Pentazocine—Anorexia—Sunitinib—kidney cancer	0.00254	0.00264	CcSEcCtD
Pentazocine—Agitation—Vincristine—kidney cancer	0.00253	0.00264	CcSEcCtD
Pentazocine—Headache—Pazopanib—kidney cancer	0.00253	0.00263	CcSEcCtD
Pentazocine—Sweating increased—Capecitabine—kidney cancer	0.00251	0.00262	CcSEcCtD
Pentazocine—Vertigo—Vincristine—kidney cancer	0.00248	0.00258	CcSEcCtD
Pentazocine—Abdominal discomfort—Capecitabine—kidney cancer	0.00247	0.00258	CcSEcCtD
Pentazocine—Dyspnoea—Sorafenib—kidney cancer	0.00247	0.00257	CcSEcCtD
Pentazocine—Visual impairment—Paclitaxel—kidney cancer	0.00242	0.00253	CcSEcCtD
Pentazocine—Insomnia—Sunitinib—kidney cancer	0.00241	0.00251	CcSEcCtD
Pentazocine—Decreased appetite—Sorafenib—kidney cancer	0.0024	0.0025	CcSEcCtD
Pentazocine—Anorexia—Dactinomycin—kidney cancer	0.0024	0.0025	CcSEcCtD
Pentazocine—Nausea—Pazopanib—kidney cancer	0.0024	0.0025	CcSEcCtD
Pentazocine—Paraesthesia—Sunitinib—kidney cancer	0.00239	0.00249	CcSEcCtD
Pentazocine—Hypertension—Vincristine—kidney cancer	0.00238	0.00248	CcSEcCtD
Pentazocine—Erythema multiforme—Paclitaxel—kidney cancer	0.00238	0.00248	CcSEcCtD
Pentazocine—Dyspnoea—Sunitinib—kidney cancer	0.00237	0.00247	CcSEcCtD
Pentazocine—Constipation—Sorafenib—kidney cancer	0.00236	0.00246	CcSEcCtD
Pentazocine—Hypersensitivity—Vinblastine—kidney cancer	0.00236	0.00246	CcSEcCtD
Pentazocine—Hypersensitivity—Everolimus—kidney cancer	0.00235	0.00245	CcSEcCtD
Pentazocine—Tinnitus—Paclitaxel—kidney cancer	0.00235	0.00244	CcSEcCtD
Pentazocine—Flushing—Paclitaxel—kidney cancer	0.00233	0.00243	CcSEcCtD
Pentazocine—Decreased appetite—Sunitinib—kidney cancer	0.00231	0.00241	CcSEcCtD
Pentazocine—Asthenia—Vinblastine—kidney cancer	0.00229	0.00239	CcSEcCtD
Pentazocine—Asthenia—Everolimus—kidney cancer	0.00229	0.00238	CcSEcCtD
Pentazocine—Constipation—Sunitinib—kidney cancer	0.00228	0.00237	CcSEcCtD
Pentazocine—Hypertension—Gemcitabine—kidney cancer	0.00226	0.00235	CcSEcCtD
Pentazocine—Chills—Paclitaxel—kidney cancer	0.00226	0.00235	CcSEcCtD
Pentazocine—Pruritus—Everolimus—kidney cancer	0.00225	0.00235	CcSEcCtD
Pentazocine—Anaphylactic shock—Vincristine—kidney cancer	0.00225	0.00235	CcSEcCtD
Pentazocine—Asthenia—Erlotinib—kidney cancer	0.00221	0.0023	CcSEcCtD
Pentazocine—Hepatic function abnormal—Doxorubicin—kidney cancer	0.0022	0.00229	CcSEcCtD
Pentazocine—Decreased appetite—Dactinomycin—kidney cancer	0.00219	0.00228	CcSEcCtD
Pentazocine—Diarrhoea—Vinblastine—kidney cancer	0.00219	0.00228	CcSEcCtD
Pentazocine—Diarrhoea—Everolimus—kidney cancer	0.00218	0.00227	CcSEcCtD
Pentazocine—Hyperhidrosis—Vincristine—kidney cancer	0.00218	0.00227	CcSEcCtD
Pentazocine—Pruritus—Erlotinib—kidney cancer	0.00217	0.00227	CcSEcCtD
Pentazocine—Agranulocytosis—Capecitabine—kidney cancer	0.00215	0.00224	CcSEcCtD
Pentazocine—Anorexia—Vincristine—kidney cancer	0.00215	0.00224	CcSEcCtD
Pentazocine—Dysgeusia—Paclitaxel—kidney cancer	0.00214	0.00223	CcSEcCtD
Pentazocine—Anaphylactic shock—Gemcitabine—kidney cancer	0.00213	0.00222	CcSEcCtD
Pentazocine—Dizziness—Vinblastine—kidney cancer	0.00211	0.0022	CcSEcCtD
Pentazocine—Dizziness—Everolimus—kidney cancer	0.00211	0.0022	CcSEcCtD
Pentazocine—Muscle spasms—Paclitaxel—kidney cancer	0.00211	0.00219	CcSEcCtD
Pentazocine—Diarrhoea—Erlotinib—kidney cancer	0.0021	0.00219	CcSEcCtD
Pentazocine—Hypotension—Vincristine—kidney cancer	0.0021	0.00219	CcSEcCtD
Pentazocine—Feeling abnormal—Dactinomycin—kidney cancer	0.00208	0.00216	CcSEcCtD
Pentazocine—Vision blurred—Paclitaxel—kidney cancer	0.00206	0.00215	CcSEcCtD
Pentazocine—Hyperhidrosis—Gemcitabine—kidney cancer	0.00206	0.00215	CcSEcCtD
Pentazocine—Tremor—Paclitaxel—kidney cancer	0.00205	0.00214	CcSEcCtD
Pentazocine—Hypersensitivity—Sorafenib—kidney cancer	0.00204	0.00212	CcSEcCtD
Pentazocine—Insomnia—Vincristine—kidney cancer	0.00204	0.00212	CcSEcCtD
Pentazocine—Anorexia—Gemcitabine—kidney cancer	0.00203	0.00212	CcSEcCtD
Pentazocine—Vomiting—Vinblastine—kidney cancer	0.00203	0.00212	CcSEcCtD
Pentazocine—Dizziness—Erlotinib—kidney cancer	0.00203	0.00212	CcSEcCtD
Pentazocine—Vomiting—Everolimus—kidney cancer	0.00203	0.00211	CcSEcCtD
Pentazocine—Paraesthesia—Vincristine—kidney cancer	0.00202	0.00211	CcSEcCtD
Pentazocine—Agitation—Paclitaxel—kidney cancer	0.00201	0.0021	CcSEcCtD
Pentazocine—Dermatitis—Everolimus—kidney cancer	0.00201	0.00209	CcSEcCtD
Pentazocine—Headache—Vinblastine—kidney cancer	0.002	0.00209	CcSEcCtD
Pentazocine—Headache—Everolimus—kidney cancer	0.002	0.00208	CcSEcCtD
Pentazocine—Hypotension—Gemcitabine—kidney cancer	0.00199	0.00208	CcSEcCtD
Pentazocine—Visual impairment—Capecitabine—kidney cancer	0.00199	0.00207	CcSEcCtD
Pentazocine—Asthenia—Sorafenib—kidney cancer	0.00198	0.00207	CcSEcCtD
Pentazocine—Vertigo—Paclitaxel—kidney cancer	0.00197	0.00205	CcSEcCtD
Pentazocine—Syncope—Paclitaxel—kidney cancer	0.00196	0.00205	CcSEcCtD
Pentazocine—Hypersensitivity—Sunitinib—kidney cancer	0.00196	0.00204	CcSEcCtD
Pentazocine—Decreased appetite—Vincristine—kidney cancer	0.00196	0.00204	CcSEcCtD
Pentazocine—Pruritus—Sorafenib—kidney cancer	0.00196	0.00204	CcSEcCtD
Pentazocine—Vomiting—Erlotinib—kidney cancer	0.00195	0.00204	CcSEcCtD
Pentazocine—Erythema multiforme—Capecitabine—kidney cancer	0.00195	0.00203	CcSEcCtD
Pentazocine—Dermatitis—Erlotinib—kidney cancer	0.00194	0.00202	CcSEcCtD
Pentazocine—Insomnia—Gemcitabine—kidney cancer	0.00193	0.00201	CcSEcCtD
Pentazocine—Headache—Erlotinib—kidney cancer	0.00193	0.00201	CcSEcCtD
Pentazocine—Tinnitus—Capecitabine—kidney cancer	0.00192	0.00201	CcSEcCtD
Pentazocine—Loss of consciousness—Paclitaxel—kidney cancer	0.00192	0.00201	CcSEcCtD
Pentazocine—Constipation—Vincristine—kidney cancer	0.00192	0.00201	CcSEcCtD
Pentazocine—Diplopia—Doxorubicin—kidney cancer	0.00192	0.002	CcSEcCtD
Pentazocine—Paraesthesia—Gemcitabine—kidney cancer	0.00192	0.002	CcSEcCtD
Pentazocine—Flushing—Capecitabine—kidney cancer	0.00192	0.002	CcSEcCtD
Pentazocine—Asthenia—Sunitinib—kidney cancer	0.00191	0.00199	CcSEcCtD
Pentazocine—Dyspnoea—Gemcitabine—kidney cancer	0.0019	0.00198	CcSEcCtD
Pentazocine—Nausea—Vinblastine—kidney cancer	0.0019	0.00198	CcSEcCtD
Pentazocine—Somnolence—Gemcitabine—kidney cancer	0.0019	0.00198	CcSEcCtD
Pentazocine—Nausea—Everolimus—kidney cancer	0.00189	0.00197	CcSEcCtD
Pentazocine—Diarrhoea—Sorafenib—kidney cancer	0.00189	0.00197	CcSEcCtD
Pentazocine—Hypertension—Paclitaxel—kidney cancer	0.00189	0.00197	CcSEcCtD
Pentazocine—Pruritus—Sunitinib—kidney cancer	0.00188	0.00196	CcSEcCtD
Pentazocine—Face oedema—Doxorubicin—kidney cancer	0.00186	0.00194	CcSEcCtD
Pentazocine—Decreased appetite—Gemcitabine—kidney cancer	0.00186	0.00193	CcSEcCtD
Pentazocine—Hypersensitivity—Dactinomycin—kidney cancer	0.00186	0.00193	CcSEcCtD
Pentazocine—Chills—Capecitabine—kidney cancer	0.00185	0.00193	CcSEcCtD
Pentazocine—Dizziness—Sorafenib—kidney cancer	0.00183	0.00191	CcSEcCtD
Pentazocine—Constipation—Gemcitabine—kidney cancer	0.00183	0.0019	CcSEcCtD
Pentazocine—Nausea—Erlotinib—kidney cancer	0.00183	0.0019	CcSEcCtD
Pentazocine—Dry mouth—Paclitaxel—kidney cancer	0.00182	0.0019	CcSEcCtD
Pentazocine—Diarrhoea—Sunitinib—kidney cancer	0.00182	0.0019	CcSEcCtD
Pentazocine—Asthenia—Dactinomycin—kidney cancer	0.00181	0.00188	CcSEcCtD
Pentazocine—Confusional state—Paclitaxel—kidney cancer	0.0018	0.00188	CcSEcCtD
Pentazocine—Anaphylactic shock—Paclitaxel—kidney cancer	0.00179	0.00186	CcSEcCtD
Pentazocine—Dysgeusia—Capecitabine—kidney cancer	0.00176	0.00183	CcSEcCtD
Pentazocine—Dizziness—Sunitinib—kidney cancer	0.00176	0.00183	CcSEcCtD
Pentazocine—Feeling abnormal—Gemcitabine—kidney cancer	0.00176	0.00183	CcSEcCtD
Pentazocine—Shock—Paclitaxel—kidney cancer	0.00176	0.00183	CcSEcCtD
Pentazocine—Vomiting—Sorafenib—kidney cancer	0.00176	0.00183	CcSEcCtD
Pentazocine—Tachycardia—Paclitaxel—kidney cancer	0.00174	0.00182	CcSEcCtD
Pentazocine—Dermatitis—Sorafenib—kidney cancer	0.00174	0.00182	CcSEcCtD
Pentazocine—Toxic epidermal necrolysis—Doxorubicin—kidney cancer	0.00173	0.00181	CcSEcCtD
Pentazocine—Headache—Sorafenib—kidney cancer	0.00173	0.00181	CcSEcCtD
Pentazocine—Muscle spasms—Capecitabine—kidney cancer	0.00173	0.0018	CcSEcCtD
Pentazocine—Hyperhidrosis—Paclitaxel—kidney cancer	0.00173	0.0018	CcSEcCtD
Pentazocine—Diarrhoea—Dactinomycin—kidney cancer	0.00172	0.0018	CcSEcCtD
Pentazocine—Anorexia—Paclitaxel—kidney cancer	0.0017	0.00178	CcSEcCtD
Pentazocine—Vision blurred—Capecitabine—kidney cancer	0.00169	0.00177	CcSEcCtD
Pentazocine—Vomiting—Sunitinib—kidney cancer	0.00169	0.00176	CcSEcCtD
Pentazocine—Tremor—Capecitabine—kidney cancer	0.00168	0.00175	CcSEcCtD
Pentazocine—Dermatitis—Sunitinib—kidney cancer	0.00168	0.00175	CcSEcCtD
Pentazocine—Hypotension—Paclitaxel—kidney cancer	0.00167	0.00174	CcSEcCtD
Pentazocine—Headache—Sunitinib—kidney cancer	0.00167	0.00174	CcSEcCtD
Pentazocine—Hypersensitivity—Vincristine—kidney cancer	0.00166	0.00173	CcSEcCtD
Pentazocine—Eosinophilia—Doxorubicin—kidney cancer	0.00165	0.00172	CcSEcCtD
Pentazocine—Nausea—Sorafenib—kidney cancer	0.00164	0.00171	CcSEcCtD
Pentazocine—Insomnia—Paclitaxel—kidney cancer	0.00162	0.00168	CcSEcCtD
Pentazocine—Vertigo—Capecitabine—kidney cancer	0.00161	0.00168	CcSEcCtD
Pentazocine—Asthenia—Vincristine—kidney cancer	0.00161	0.00168	CcSEcCtD
Pentazocine—Syncope—Capecitabine—kidney cancer	0.00161	0.00168	CcSEcCtD
Pentazocine—Paraesthesia—Paclitaxel—kidney cancer	0.00161	0.00167	CcSEcCtD
Pentazocine—Vomiting—Dactinomycin—kidney cancer	0.0016	0.00167	CcSEcCtD
Pentazocine—Dyspnoea—Paclitaxel—kidney cancer	0.00159	0.00166	CcSEcCtD
Pentazocine—Somnolence—Paclitaxel—kidney cancer	0.00159	0.00166	CcSEcCtD
Pentazocine—Nausea—Sunitinib—kidney cancer	0.00158	0.00165	CcSEcCtD
Pentazocine—Loss of consciousness—Capecitabine—kidney cancer	0.00158	0.00165	CcSEcCtD
Pentazocine—Decreased appetite—Paclitaxel—kidney cancer	0.00155	0.00162	CcSEcCtD
Pentazocine—Hypertension—Capecitabine—kidney cancer	0.00155	0.00162	CcSEcCtD
Pentazocine—Diarrhoea—Vincristine—kidney cancer	0.00154	0.0016	CcSEcCtD
Pentazocine—Asthenia—Gemcitabine—kidney cancer	0.00153	0.0016	CcSEcCtD
Pentazocine—Constipation—Paclitaxel—kidney cancer	0.00153	0.00159	CcSEcCtD
Pentazocine—Pruritus—Gemcitabine—kidney cancer	0.00151	0.00157	CcSEcCtD
Pentazocine—Dry mouth—Capecitabine—kidney cancer	0.0015	0.00156	CcSEcCtD
Pentazocine—Nausea—Dactinomycin—kidney cancer	0.0015	0.00156	CcSEcCtD
Pentazocine—Dizziness—Vincristine—kidney cancer	0.00149	0.00155	CcSEcCtD
Pentazocine—Confusional state—Capecitabine—kidney cancer	0.00148	0.00154	CcSEcCtD
Pentazocine—Feeling abnormal—Paclitaxel—kidney cancer	0.00147	0.00153	CcSEcCtD
Pentazocine—Diarrhoea—Gemcitabine—kidney cancer	0.00146	0.00152	CcSEcCtD
Pentazocine—Shock—Capecitabine—kidney cancer	0.00144	0.0015	CcSEcCtD
Pentazocine—Tachycardia—Capecitabine—kidney cancer	0.00143	0.00149	CcSEcCtD
Pentazocine—Vomiting—Vincristine—kidney cancer	0.00143	0.00149	CcSEcCtD
Pentazocine—Sweating—Doxorubicin—kidney cancer	0.00142	0.00148	CcSEcCtD
Pentazocine—Hyperhidrosis—Capecitabine—kidney cancer	0.00142	0.00148	CcSEcCtD
Pentazocine—Dermatitis—Vincristine—kidney cancer	0.00142	0.00148	CcSEcCtD
Pentazocine—Headache—Vincristine—kidney cancer	0.00141	0.00147	CcSEcCtD
Pentazocine—Anorexia—Capecitabine—kidney cancer	0.0014	0.00146	CcSEcCtD
Pentazocine—Agranulocytosis—Doxorubicin—kidney cancer	0.00138	0.00144	CcSEcCtD
Pentazocine—Hypotension—Capecitabine—kidney cancer	0.00137	0.00143	CcSEcCtD
Pentazocine—Vomiting—Gemcitabine—kidney cancer	0.00136	0.00141	CcSEcCtD
Pentazocine—Dermatitis—Gemcitabine—kidney cancer	0.00134	0.0014	CcSEcCtD
Pentazocine—Headache—Gemcitabine—kidney cancer	0.00134	0.00139	CcSEcCtD
Pentazocine—Nausea—Vincristine—kidney cancer	0.00134	0.00139	CcSEcCtD
Pentazocine—Insomnia—Capecitabine—kidney cancer	0.00133	0.00138	CcSEcCtD
Pentazocine—Paraesthesia—Capecitabine—kidney cancer	0.00132	0.00137	CcSEcCtD
Pentazocine—Hypersensitivity—Paclitaxel—kidney cancer	0.00132	0.00137	CcSEcCtD
Pentazocine—Dyspnoea—Capecitabine—kidney cancer	0.00131	0.00136	CcSEcCtD
Pentazocine—Visual impairment—Doxorubicin—kidney cancer	0.00128	0.00134	CcSEcCtD
Pentazocine—Asthenia—Paclitaxel—kidney cancer	0.00128	0.00134	CcSEcCtD
Pentazocine—Decreased appetite—Capecitabine—kidney cancer	0.00128	0.00133	CcSEcCtD
Pentazocine—Nausea—Gemcitabine—kidney cancer	0.00127	0.00132	CcSEcCtD
Pentazocine—Pruritus—Paclitaxel—kidney cancer	0.00126	0.00132	CcSEcCtD
Pentazocine—Erythema multiforme—Doxorubicin—kidney cancer	0.00126	0.00131	CcSEcCtD
Pentazocine—Constipation—Capecitabine—kidney cancer	0.00125	0.00131	CcSEcCtD
Pentazocine—Tinnitus—Doxorubicin—kidney cancer	0.00124	0.00129	CcSEcCtD
Pentazocine—Flushing—Doxorubicin—kidney cancer	0.00124	0.00129	CcSEcCtD
Pentazocine—Diarrhoea—Paclitaxel—kidney cancer	0.00122	0.00127	CcSEcCtD
Pentazocine—Feeling abnormal—Capecitabine—kidney cancer	0.00121	0.00126	CcSEcCtD
Pentazocine—Chills—Doxorubicin—kidney cancer	0.00119	0.00124	CcSEcCtD
Pentazocine—Dizziness—Paclitaxel—kidney cancer	0.00118	0.00123	CcSEcCtD
Pentazocine—Vomiting—Paclitaxel—kidney cancer	0.00114	0.00118	CcSEcCtD
Pentazocine—Dysgeusia—Doxorubicin—kidney cancer	0.00113	0.00118	CcSEcCtD
Pentazocine—Dermatitis—Paclitaxel—kidney cancer	0.00113	0.00117	CcSEcCtD
Pentazocine—Headache—Paclitaxel—kidney cancer	0.00112	0.00117	CcSEcCtD
Pentazocine—Muscle spasms—Doxorubicin—kidney cancer	0.00111	0.00116	CcSEcCtD
Pentazocine—Vision blurred—Doxorubicin—kidney cancer	0.00109	0.00114	CcSEcCtD
Pentazocine—Hypersensitivity—Capecitabine—kidney cancer	0.00108	0.00113	CcSEcCtD
Pentazocine—Agitation—Doxorubicin—kidney cancer	0.00106	0.00111	CcSEcCtD
Pentazocine—Nausea—Paclitaxel—kidney cancer	0.00106	0.00111	CcSEcCtD
Pentazocine—Asthenia—Capecitabine—kidney cancer	0.00105	0.0011	CcSEcCtD
Pentazocine—Vertigo—Doxorubicin—kidney cancer	0.00104	0.00108	CcSEcCtD
Pentazocine—Syncope—Doxorubicin—kidney cancer	0.00104	0.00108	CcSEcCtD
Pentazocine—Pruritus—Capecitabine—kidney cancer	0.00104	0.00108	CcSEcCtD
Pentazocine—Loss of consciousness—Doxorubicin—kidney cancer	0.00102	0.00106	CcSEcCtD
Pentazocine—Diarrhoea—Capecitabine—kidney cancer	0.001	0.00105	CcSEcCtD
Pentazocine—Hypertension—Doxorubicin—kidney cancer	0.001	0.00104	CcSEcCtD
Pentazocine—Dizziness—Capecitabine—kidney cancer	0.00097	0.00101	CcSEcCtD
Pentazocine—Dry mouth—Doxorubicin—kidney cancer	0.000965	0.00101	CcSEcCtD
Pentazocine—Confusional state—Doxorubicin—kidney cancer	0.000953	0.000993	CcSEcCtD
Pentazocine—Anaphylactic shock—Doxorubicin—kidney cancer	0.000946	0.000985	CcSEcCtD
Pentazocine—Vomiting—Capecitabine—kidney cancer	0.000933	0.000972	CcSEcCtD
Pentazocine—Shock—Doxorubicin—kidney cancer	0.00093	0.000969	CcSEcCtD
Pentazocine—Dermatitis—Capecitabine—kidney cancer	0.000924	0.000963	CcSEcCtD
Pentazocine—Tachycardia—Doxorubicin—kidney cancer	0.000923	0.000962	CcSEcCtD
Pentazocine—Headache—Capecitabine—kidney cancer	0.000919	0.000958	CcSEcCtD
Pentazocine—Hyperhidrosis—Doxorubicin—kidney cancer	0.000914	0.000952	CcSEcCtD
Pentazocine—Anorexia—Doxorubicin—kidney cancer	0.000901	0.000939	CcSEcCtD
Pentazocine—Hypotension—Doxorubicin—kidney cancer	0.000884	0.000921	CcSEcCtD
Pentazocine—Nausea—Capecitabine—kidney cancer	0.000871	0.000908	CcSEcCtD
Pentazocine—Insomnia—Doxorubicin—kidney cancer	0.000855	0.000891	CcSEcCtD
Pentazocine—Paraesthesia—Doxorubicin—kidney cancer	0.000849	0.000885	CcSEcCtD
Pentazocine—Dyspnoea—Doxorubicin—kidney cancer	0.000843	0.000878	CcSEcCtD
Pentazocine—Somnolence—Doxorubicin—kidney cancer	0.000841	0.000876	CcSEcCtD
Pentazocine—Decreased appetite—Doxorubicin—kidney cancer	0.000822	0.000857	CcSEcCtD
Pentazocine—Constipation—Doxorubicin—kidney cancer	0.000809	0.000843	CcSEcCtD
Pentazocine—Feeling abnormal—Doxorubicin—kidney cancer	0.000779	0.000812	CcSEcCtD
Pentazocine—Hypersensitivity—Doxorubicin—kidney cancer	0.000697	0.000726	CcSEcCtD
Pentazocine—Asthenia—Doxorubicin—kidney cancer	0.000678	0.000707	CcSEcCtD
Pentazocine—Pruritus—Doxorubicin—kidney cancer	0.000669	0.000697	CcSEcCtD
Pentazocine—Diarrhoea—Doxorubicin—kidney cancer	0.000647	0.000674	CcSEcCtD
Pentazocine—Dizziness—Doxorubicin—kidney cancer	0.000625	0.000652	CcSEcCtD
Pentazocine—Vomiting—Doxorubicin—kidney cancer	0.000601	0.000626	CcSEcCtD
Pentazocine—Dermatitis—Doxorubicin—kidney cancer	0.000596	0.000621	CcSEcCtD
Pentazocine—Headache—Doxorubicin—kidney cancer	0.000592	0.000617	CcSEcCtD
Pentazocine—Nausea—Doxorubicin—kidney cancer	0.000562	0.000585	CcSEcCtD
